This morning, the House will consider H.R. 19, a Republican amendment to Speaker Pelosi’s radical and partisan drug pricing scheme. Unlike H.R. 3, the Lower Costs, More Cures Act (H.R. 19) encourages innovation of new cures, promotes low-cost options for patients, and improves transparency and accountability.
On the House floor, Rep. Virginia Foxx (R-NC), Republican Leader of the Education and Labor Committee, delivered the following remarks (as prepared for delivery):
"Democrats are putting politics over progress by advancing a socialist drug-pricing scheme that will hurt the development of money-saving treatments and-more importantly- people’s lives. Sadly, workers and families are being let down by Democrats.
"That is why I’m proud to sponsor and support H.R. 19, the Lower Costs, More Cures Act. This legislation includes 40 provisions backed by Democrats and Republicans and it can go to the President’s desk today.
"Unlike H.R. 3, which the nonpartisan Congressional Budget Office predicts will result in 38 fewer cures, H.R. 19 protects access to new medicines and cures. It also lowers out-of-pocket spending, strengthens transparency and accountability, and champions competition.
"The Lower Costs, More Cures Act is policy that acts in the interest of hardworking Americans. I urge my colleagues to support this bipartisan, commonsense amendment."
